Trials / Completed
CompletedNCT02866032
Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 452 (actual)
- Sponsor
- Moberg Pharma AB · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MOB015B | |
| DRUG | Ciclopirox 80 mg/g |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2020-06-10
- Completion
- 2020-06-10
- First posted
- 2016-08-15
- Last updated
- 2020-10-06
Locations
3 sites across 3 countries: Germany, Poland, United Kingdom
Source: ClinicalTrials.gov record NCT02866032. Inclusion in this directory is not an endorsement.